ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Hot Features

Registration Strip Icon for charts Registrieren Sie sich für Echtzeit-Charts, Analysetools und Preise.
Endo International PLC

Endo International PLC (ENDP)

0,2926
0,00
(0,00%)
Geschlossen 24 November 10:00PM
0,00
0,00
(0,00%)
Nach Börsenschluss: -

Professionelle Tools für Privatanleger.

Wichtige Statistiken und Details

Current Price
0,2926
Gebot
0,29
Fragen
0,294
Volumen
-
0,00 Tagesbereich 0,00
0,00 52-Wochen-Bereich 0,00
Marktkapitalisierung
Handelsende
0,2926
Handelsbeginn
-
Letzte Trade
Letzter Handelszeitpunkt
Finanzvolumen
-
VWAP
-
Durchschnittliches Volumen (3 Mio.)
-
Ausgegebene Aktien
235.220.000
Dividendenrendite
-
Kurs-Gewinn-Verhältnis
-0,03
Gewinn pro Aktie (EPS)
-10,42
Erlöse
2,01B
Nettogewinn
-2,45B

Über Endo International PLC

Endo International PLC is a specialty pharmaceutical company with a considerable presence in pain management, urology, orthopedics, endocrinology, bariatrics, and others. It operates in four segments: Branded Pharmaceuticals, Sterile Injectables, Generic Pharmaceuticals, and International Pharmaceut... Endo International PLC is a specialty pharmaceutical company with a considerable presence in pain management, urology, orthopedics, endocrinology, bariatrics, and others. It operates in four segments: Branded Pharmaceuticals, Sterile Injectables, Generic Pharmaceuticals, and International Pharmaceuticals. Some of its products include XIAFLEX, SUPPRELIN, PERCOCET, TESTOPEL, VASOSTRICT, ADRENALIN, and APLISOL. The majority of its revenue comes from the United States. Mehr anzeigen

Sektor
Pharmaceutical Preparations
Branche
Pharmaceutical Preparations
Website
Hauptsitz
Dublin, Irl
Gegründet
-

ENDP Neueste Nachrichten

Endo Presents New Data at the American Orthopaedic Foot & Ankle Society Annual Meeting

Endo Presents New Data at the American Orthopaedic Foot & Ankle Society Annual Meeting PR Newswire DUBLIN, Sept. 21, 2023 DUBLIN, Sept. 21, 2023 /PRNewswire/ -- Endo International plc (OTC:...

ENDO REPORTS SECOND-QUARTER 2023 FINANCIAL RESULTS

ENDO REPORTS SECOND-QUARTER 2023 FINANCIAL RESULTS PR Newswire DUBLIN, Aug. 8, 2023 DUBLIN, Aug. 8, 2023 /PRNewswire/ -- Endo International plc (OTC: ENDPQ) today reported financial results for...

Endo Launches Bivalirudin Injection in Ready-to-Use Vials

Endo Launches Bivalirudin Injection in Ready-to-Use Vials PR Newswire DUBLIN, July 18, 2023 Only ready-to-use liquid format of bivalirudin on the marketDoes not require reconstitution, dilution...

Endo Presents New Data at the American Podiatric Medical Association Annual Meeting

Endo Presents New Data at the American Podiatric Medical Association Annual Meeting PR Newswire DUBLIN, July 13, 2023 DUBLIN, July 13, 2023 /PRNewswire/ -- Endo International plc (OTC: ENDPQ...

Endo Launches PREVDUO™ (neostigmine methylsulfate and glycopyrrolate injection), the First and Only FDA-Approved Neostigmine-Glycopyrrolate Combination Pre-Filled Syringe

Endo Launches PREVDUO™ (neostigmine methylsulfate and glycopyrrolate injection), the First and Only FDA-Approved Neostigmine-Glycopyrrolate Combination Pre-Filled Syringe PR Newswire DUBLIN, June...

ENDO REPORTS FIRST-QUARTER 2023 FINANCIAL RESULTS

ENDO REPORTS FIRST-QUARTER 2023 FINANCIAL RESULTS PR Newswire DUBLIN, May 8, 2023 DUBLIN, May 8, 2023 /PRNewswire/ -- Endo International plc (OTC: ENDPQ) today reported financial results for the...

Endo Announces Launch of Argatroban Injection Through Premier's ProRx® Private-Label Program

Endo Announces Launch of Argatroban Injection Through Premier's ProRx® Private-Label Program PR Newswire DUBLIN, April 17, 2023 DUBLIN, April 17, 2023 /PRNewswire/ -- Endo International plc (OTC:...

Endo Launches Authorized Generic Version of Noxafil® (posaconazole) Oral Suspension

Endo Launches Authorized Generic Version of Noxafil® (posaconazole) Oral Suspension PR Newswire DUBLIN, April 3, 2023 DUBLIN, April 3, 2023 /PRNewswire/ -- Endo International plc (OTC: ENDPQ...

Endo Provides Top-Line Results from Phase 2 Study of Collagenase Clostridium Histolyticum (CCH) in Participants With Plantar Fibromatosis

Endo Provides Top-Line Results from Phase 2 Study of Collagenase Clostridium Histolyticum (CCH) in Participants With Plantar Fibromatosis PR Newswire DUBLIN, March 13, 2023 DUBLIN, March 13, 2023...

Zeitraum †ÄnderungÄnderung %HandelsbeginnHochNiedrigDurchsch. VolumenVWAP
10000000CS
40000000CS
120000000CS
260000000CS
520000000CS
1560000000CS
2600000000CS
  • Volumen
  • % Tops
  • % Flops
SymbolPreisVol.
PDYNPalladyne AI Corporation
US$ 4,59
(129,50%)
83,07M
QMCOQuantum Corporation
US$ 9,11
(126,62%)
39,48M
NANano Labs Ltd
US$ 8,26
(89,02%)
2,03M
XCURExicure Inc
US$ 18,60
(71,27%)
4,59M
SKKSKK Holdings Limited
US$ 1,75
(59,09%)
107,47M
AMIXAutonomix Medical Inc
US$ 6,21
(-54,07%)
946,09k
CETXCemtrex Inc
US$ 0,1146
(-41,74%)
24,39M
MSWMing Shing Group Holdings Ltd
 5,90
(-35,52%)
417,08k
RMSGReal Messenger Corporation
US$ 3,09
(-26,25%)
313,51k
ENSCEnsysce Biosciences Inc
US$ 0,4414
(-25,49%)
4M
ELABElevai Labs Inc
US$ 0,0201
(-0,50%)
415,87M
NVDANVIDIA Corporation
US$ 141,95
(-3,22%)
229,93M
SMCISuper Micro Computer Inc
US$ 33,15
(11,62%)
155,43M
VRPXVirpax Pharmaceuticals Inc
US$ 0,5501
(-6,72%)
154,17M
SOUNSoundHound AI Inc
US$ 8,24
(18,05%)
103,6M
Keine Diskussionen Gefunden.
Neuen Thread Erstellen

Kürzlich von Ihnen besucht

Delayed Upgrade Clock